UNSPSC 51333414: Ziprasidone hydrochloride hydrate

This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 216X081ORU, chemically known as 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-, hydrochloride, hydrate (1:1:1), but more generally known as ziprasidone hydrochloride hydrate, which bears US NIH Compound Identifier 60853.

European Medicines Agency schedules ziprasidone hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00168MIG. Most nations, for tariff purposes, schedule ziprasidone hydrochloride hydrate under HS 29341000. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)CCC4CC5C(CC4CL)NC(=O)C5.O.CL.

UNSPSC 51333414 Ziprasidone hydrochloride hydrate is a Commodity code that designates a specific psychiatric antipsychotic medication, yet the recent state and local opportunities posted under this code show significant scope mismatch—the Seminole County and Texas HHS solicitations address naloxone, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals broadly, not ziprasidone specifically. State and local procurement activity under this code reflects a broader pattern of pharmaceutical and over-the-counter product sourcing rather than procurement of ziprasidone as a discrete line item. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving multiple state and local participants across at least Minnesota and Oregon). These jurisdictions are sourcing pharmaceutical products through competitive bidding (IFB), exploratory requests for information (RFI), and cooperative RFPs that distribute contracts across authorized wholesalers and manufacturers.

Recent solicitation activity spans Florida, Texas, and the upper Midwest. Seminole County issued IFB60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for implementing direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP issued an RFP (S1070000015802) on January 20, 2026, with a March 26, 2026, response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with pricing evaluation weighted 75 percent on price competitiveness and 25 percent combined on fixed pricing, administrative compliance, EDI capability, and administrative fee acceptance.